SELPAC: A 3 arm randomised phase II study of the MEK inhibitor selumetinib alone or in combination with paclitaxel (PT) in metastatic uveal melanoma (UM)

P. Nathan; A. Needham; P. G. Corrie; S. Danson; J. Evans; S. Ochsenreither; S. Kumar; A. Goodman; J. M. G. Larkin; I. Karydis; N. M. Steven; P. Lorigan; R. Plummer; P. Patel; H. M. Shaw; S. Leyvraz; C. Rawcliffe; E. E. Psarelli; L. Handley; J. J. Sacco

SELPAC: A 3 arm randomised phase II study of the MEK inhibitor selumetinib alone or in combination with paclitaxel (PT) in metastatic uveal melanoma (UM)

P. Nathan, A. Needham, P. G. Corrie, S. Danson, J. Evans, S. Ochsenreither, S. Kumar, A. Goodman, J. M. G. Larkin, I. Karydis, N. M. Steven, P. Lorigan, R. Plummer, P. Patel, H. M. Shaw, S. Leyvraz, C. Rawcliffe, E. E. Psarelli, L. Handley, J. J. Sacco

Research output: Contribution to journal › Meeting Abstract › peer-review

Original language	English
Journal	Annals of Oncology
Volume	30
Publication status	Published - Oct 2019

Research Beacons, Institutes and Platforms

Manchester Cancer Research Centre

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Cite this

Nathan, P., Needham, A., Corrie, P. G., Danson, S., Evans, J., Ochsenreither, S., Kumar, S., Goodman, A., Larkin, J. M. G., Karydis, I., Steven, N. M., Lorigan, P., Plummer, R., Patel, P., Shaw, H. M., Leyvraz, S., Rawcliffe, C., Psarelli, E. E., Handley, L., & Sacco, J. J. (2019). SELPAC: A 3 arm randomised phase II study of the MEK inhibitor selumetinib alone or in combination with paclitaxel (PT) in metastatic uveal melanoma (UM). Annals of Oncology, 30.

@article{d62fa2cba75446f0bbcd37b30f39d752,

title = "SELPAC: A 3 arm randomised phase II study of the MEK inhibitor selumetinib alone or in combination with paclitaxel (PT) in metastatic uveal melanoma (UM)",

author = "P. Nathan and A. Needham and Corrie, {P. G.} and S. Danson and J. Evans and S. Ochsenreither and S. Kumar and A. Goodman and Larkin, {J. M. G.} and I. Karydis and Steven, {N. M.} and P. Lorigan and R. Plummer and P. Patel and Shaw, {H. M.} and S. Leyvraz and C. Rawcliffe and Psarelli, {E. E.} and L. Handley and Sacco, {J. J.}",

year = "2019",

month = oct,

language = "English",

volume = "30",

journal = "Annals of Oncology",

issn = "0923-7534",

publisher = "Elsevier BV",

}

Nathan, P, Needham, A, Corrie, PG, Danson, S, Evans, J, Ochsenreither, S, Kumar, S, Goodman, A, Larkin, JMG, Karydis, I, Steven, NM, Lorigan, P, Plummer, R, Patel, P, Shaw, HM, Leyvraz, S, Rawcliffe, C, Psarelli, EE, Handley, L & Sacco, JJ 2019, 'SELPAC: A 3 arm randomised phase II study of the MEK inhibitor selumetinib alone or in combination with paclitaxel (PT) in metastatic uveal melanoma (UM)', Annals of Oncology, vol. 30.

TY - JOUR

T1 - SELPAC: A 3 arm randomised phase II study of the MEK inhibitor selumetinib alone or in combination with paclitaxel (PT) in metastatic uveal melanoma (UM)

AU - Nathan, P.

AU - Needham, A.

AU - Corrie, P. G.

AU - Danson, S.

AU - Evans, J.

AU - Ochsenreither, S.

AU - Kumar, S.

AU - Goodman, A.

AU - Larkin, J. M. G.

AU - Karydis, I.

AU - Steven, N. M.

AU - Lorigan, P.

AU - Plummer, R.

AU - Patel, P.

AU - Shaw, H. M.

AU - Leyvraz, S.

AU - Rawcliffe, C.

AU - Psarelli, E. E.

AU - Handley, L.

AU - Sacco, J. J.

PY - 2019/10

Y1 - 2019/10

M3 - Meeting Abstract

SN - 0923-7534

VL - 30

JO - Annals of Oncology

JF - Annals of Oncology

ER -